niacinamide has been researched along with Infections, Coronavirus in 6 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This crucial role can be attributed to the gut microflora and its ability to shape human behavior and development by mediating the bioavailability of metabolites." | 2.66 | Minireview Exploring the Biological Cycle of Vitamin B3 and Its Influence on Oxidative Stress: Further Molecular and Clinical Aspects. ( Anton, E; Ciobica, A; Cojocariu, RO; Dhunna, N; Doroftei, B; Grab, D; Ilie, OD; Maftei, R; McKenna, J; Simionescu, G, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, M | 1 |
| Zhang, L | 1 |
| Pan, L | 1 |
| Zhou, P | 1 |
| Yu, R | 1 |
| Zhang, Z | 1 |
| Lv, J | 1 |
| Guo, H | 1 |
| Wang, Y | 1 |
| Xiao, S | 1 |
| Liu, X | 1 |
| Mehmel, M | 1 |
| Jovanović, N | 1 |
| Spitz, U | 1 |
| Doroftei, B | 1 |
| Ilie, OD | 1 |
| Cojocariu, RO | 1 |
| Ciobica, A | 1 |
| Maftei, R | 1 |
| Grab, D | 1 |
| Anton, E | 1 |
| McKenna, J | 1 |
| Dhunna, N | 1 |
| Simionescu, G | 1 |
| Zhao, H | 1 |
| Mendenhall, M | 1 |
| Deininger, MW | 1 |
| Blasco, H | 1 |
| Bessy, C | 1 |
| Plantier, L | 1 |
| Lefevre, A | 1 |
| Piver, E | 1 |
| Bernard, L | 1 |
| Marlet, J | 1 |
| Stefic, K | 1 |
| Benz-de Bretagne, I | 1 |
| Cannet, P | 1 |
| Lumbu, H | 1 |
| Morel, T | 1 |
| Boulard, P | 1 |
| Andres, CR | 1 |
| Vourc'h, P | 1 |
| Hérault, O | 1 |
| Guillon, A | 1 |
| Emond, P | 1 |
| Badawy, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nicotinamide Riboside in Ulcerative Colitis[NCT05561738] | 40 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| A RANDOMIZED NON-COMPARATIVE PHASE 2 PILOT STUDY TESTING THE VALUE OF IMATINIB MESYLATE AS AN EARLY TREATMENT OF COVID-19 DISEASE IN AGED HOSPITALIZED PATIENTS.[NCT04357613] | Phase 2 | 99 participants (Anticipated) | Interventional | 2020-09-01 | Not yet recruiting | ||
| Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416] | Phase 3 | 204 participants (Anticipated) | Interventional | 2020-06-02 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for niacinamide and Infections, Coronavirus
| Article | Year |
|---|---|
Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.
Topics: Aging; Animals; Betacoronavirus; Biological Availability; Cardiovascular Diseases; Coronavirus Infec | 2020 |
Minireview Exploring the Biological Cycle of Vitamin B3 and Its Influence on Oxidative Stress: Further Molecular and Clinical Aspects.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Dysbiosis; Gastrointestinal Microbiome; Humans; N | 2020 |
Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.
Topics: Basic Helix-Loop-Helix Transcription Factors; Betacoronavirus; Cell Line; Coronavirus Infections; CO | 2020 |
3 other studies available for niacinamide and Infections, Coronavirus
| Article | Year |
|---|---|
Nicotinamide Efficiently Suppresses Porcine Epidemic Diarrhea Virus and Porcine Deltacoronavirus Replication.
Topics: Animals; Coronavirus; Coronavirus Infections; Deltacoronavirus; Diarrhea; Humans; Niacinamide; Porci | 2023 |
Imatinib is not a potent anti-SARS-CoV-2 drug.
Topics: Antiviral Agents; Betacoronavirus; Caco-2 Cells; Coronavirus Infections; COVID-19; Drug Repositionin | 2020 |
Imatinib is not a potent anti-SARS-CoV-2 drug.
Topics: Antiviral Agents; Betacoronavirus; Caco-2 Cells; Coronavirus Infections; COVID-19; Drug Repositionin | 2020 |
Imatinib is not a potent anti-SARS-CoV-2 drug.
Topics: Antiviral Agents; Betacoronavirus; Caco-2 Cells; Coronavirus Infections; COVID-19; Drug Repositionin | 2020 |
Imatinib is not a potent anti-SARS-CoV-2 drug.
Topics: Antiviral Agents; Betacoronavirus; Caco-2 Cells; Coronavirus Infections; COVID-19; Drug Repositionin | 2020 |
The specific metabolome profiling of patients infected by SARS-COV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine metabolism.
Topics: Aged; Aged, 80 and over; Betacoronavirus; Biomarkers; Coronavirus Infections; COVID-19; Cytosine; Ea | 2020 |